Clearmind Medicine is offering on a “reasonable best efforts” basis up to $7.0M of common shares of Clearmind Medicine at an assumed public offering price of 46c per common share, which was the closing price of its common shares on The Nasdaq Capital Market on July 12. The company is also offering on a “reasonable best efforts” basis pre-funded warrants to purchase up to 15.22M common shares. Aegis Capital is acting as the placement agent.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CMND:
- Clearmind Medicine Announces Share-Based Payment for the Company’s Consultants
- Clearmind Medicine appoints Fatima Cody Stanford to SAB
- Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine’s Scientific Advisory Board
- Rising High: Exclusive talk with biotech company Clearmind Medicine
- FDA issues first draft guidance on clinical trials with psychedelic drugs